A detailed history of Swiss National Bank transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Swiss National Bank holds 247,400 shares of LYEL stock, worth $150,914. This represents 0.0% of its overall portfolio holdings.

Number of Shares
247,400
Previous 247,400 -0.0%
Holding current value
$150,914
Previous $358,000 4.75%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 06, 2024

SELL
$1.39 - $2.35 $33,777 - $57,105
-24,300 Reduced 8.94%
247,400 $479,000
Q2 2023

Aug 09, 2023

BUY
$1.89 - $3.86 $513,513 - $1.05 Million
271,700 New
271,700 $864,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $151M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.